Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To...
Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To...
Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To Other Drugs; Findings Suggest TUS Will Demonstrate Broad Antileukemic Activity Across AML Patients
Aptose宣佈在AACR期刊上發佈前臨床數據，證明Tuspetinib的獨特作用機制以及與Venetoclax聯用時對AML細胞的合成致死性；Tuspetinib在對其他藥物耐藥的多個AML模型中延長生存期；研究結果表明TUS將在AML患者中展示廣泛的抗白血病活性。
- Peer-reviewed publication details unique TUS mechanism of action
- TUS+VEN combination synthetic lethality overcomes resistance to VEN
- Tuspetinib prolongs survival in multiple AML models resistant to other drugs
- Findings suggest TUS will demonstrate broad antileukemic activity across AML patients
-
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling
- 經過同行評審的出版物詳細介紹了TUS的獨特作用機制。
- TUS+VEN組合的合成致死性克服了對VEN的耐藥性。
- Tuspetinib在對其他藥物耐藥的多個AML模型中延長生存期。
- 研究結果表明TUS將在AML患者中展示廣泛的抗白血病活性。
- 目前正在招募新診斷AML患者的TUS+VEN+AZA三重前線治療。
SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the publication of preclinical data for Aptose's lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR), available online now (link).
聖地亞哥和多倫多，2024年12月12日（環球新聞通訊社）-- Aptose Biosciences Inc.（"Aptose"或"公司"）（納斯達克：APTO，TSX：APS），一家臨床階段的精準腫瘤學公司，正在開發高度差異化的靶向藥物以治療血液惡性腫瘤，今天宣佈在美國癌症研究協會（AACR）期刊《抗癌醫藥通訊》上發佈Aptose的主要血液學化合物Tuspetinib（TUS）的前臨床數據，目前在線可用（鏈接）。
The publication, entitled "Preclinical development of tuspetinib for the treatment of acute myeloid leukemia," is the first preclinical profiling of tuspetinib, a well-tolerated, once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML). The publication defines TUS activities on select oncogenic signaling targets, demonstrates enhanced activity and safety of TUS when combined with other agents, and illustrates synthetic lethality when combined with venetoclax (VEN). Pharmacokinetic and toxicology studies revealed that TUS is readily absorbed and achieves plasma concentrations sufficient to inhibit the target kinases, it has a plasma half-life that supports once daily dosing, and it demonstrates a favorable safety profile.
這篇題爲《Tuspetinib治療急性髓性白血病的前臨床開發》的出版物是對Tuspetinib的首次前臨床分析，這是一種耐受良好的、每日一次的口服激酶抑制劑，目前正在進行急性髓性白血病（AML）的臨床開發。該出版物定義了TUS對特定腫瘤信號靶標的活性，展示了TUS與其他藥物聯用時的增強活性和安全性，並說明了TUS與Venetoclax（VEN）聯用時的合成致死性。藥代動力學和毒理學研究表明，TUS被快速吸收並達到足以抑制目標激酶的血漿濃度，其血漿半衰期支持每日一次給藥，並且顯示出良好的安全性特徵。
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib + venetoclax + azacitidine (TUS+VEN+AZA) triplet combination (NCT03850574). Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or the TUS+VEN combination have been completed.
Aptose現在正在招募新診斷的急性髓性白血病（AML）患者，參與一項1/2期臨床研究，以接受tuspetinib + venetoclax + azacitidine（TUS+VEN+AZA）三聯組合（NCT03850574）。針對復發或難治性AML患者接受TUS單藥或TUS+VEN組合的臨床研究已完成。
譯文內容由第三人軟體翻譯。
